- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06021210
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
Letermovir for the Prevention of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients Based on the Outcome of Metagenomic Next-Generation Sequencing: a Phase 2, Open Label, Single-Arm Clinical Trial.
Study Overview
Status
Intervention / Treatment
Detailed Description
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used as the sole curative treatment for malignant hematological diseases. However, the chances of contracting various pathogenic bacterial infections significantly increase after transplantation, with cytomegalovirus (CMV) infection being the most prevalent [1]. The propotion of CMV-seropositive people ranges from 30% to 97%. After a previous infection, CMV can remain latent in the patient's body and reactivate when the immune function is low, which is the primary cause of CMV infection in allo-HSCT patients, leading to CMV viremia and CMV disease. If CMV viremia progresses to CMV disease, it can invade various organs such as the lungs, digestive tract, retina, and brain, with CMV pneumonia having a mortality rate of over 80% [2]. After allo-HSCT, the incidence of CMV disease ranges from 60% to 70%, depending on the serological status of the donor and recipient [3-4].
In the past, antiviral drugs including ganciclovir, foscarnet, cidofovir, and valganciclovir/valacyclovir were commonly used to treat or prevent CMV infections in clinical practice. These drugs target on viral DNA polymerase, which in turn inhibits the replication of CMV DNA. However, these drugs have serious side effects, such as bone marrow suppression and severe nephrotoxicity, which limit their clinical application.
Letermovir is the world's first and only new drug approved for the prevention of CMV infection. In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It was approved in China on December 31, 2021. Letermovir targets on the CMV DNA terminase complex consisting of pUL51, pUL56, and pUL89, which affects the formation of appropriate unit-length genomes and interferes with the maturation of virus particles. Therefore, due to its unique pharmacological mechanism, Letermovir does not affect the normal function of human cells, which can avoid the common side effects of other anti-CMV drugs, and it does not develop cross-resistance with other antiviral drugs. Letermovir does not affect the incidence and timing of hematopoietic stem cell implantation and is an effective and safe first-line drug for the prevention of CMV infection and disease after allo-HSCT. It is recommended for CMV-seropositive adult allo-HSCT recipients to use Letermovir for CMV prophylaxis from day 0 after transplantation, no later than day 28 after transplantation (can be used before implantation), and continue until day 100 after transplantation.
The mNGS (metagenomic next-generation sequencing) detection method is a new high-throughput sequencing method for analyzing the microbiome in clinical samples, independent of traditional microbial cultivation. It involves extracting nucleic acid sequences from the samples, constructing sequencing libraries, sequencing the nucleic acid sequences in the sample, and comparing them to a microbial-specific database for analysis. Through intelligent algorithms, it identifies the species information of suspected pathogenic microorganisms with high sensitivity. The mNGS method can detect potential CMV infection in patients before having positive outcomes in qPCR detection of CMV-DNA, and has been used clinically.
This study will evaluate the efficacy and safety of using letermovir to prevent CMV reactivation for high-risk patients with pre-existing CMV viremia based on the mNGS detection technology before HSCT.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Xiaowen Tang, PhD
- Phone Number: 67781525
- Email: xwtang1020@163.com
Study Contact Backup
- Name: Depei Wu, PhD
- Phone Number: 67781525
- Email: drwudepei@163.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Contact:
- Xiaowen Tang, PhD
- Phone Number: 67781525
- Email: xwtang1020@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- HSCT candidate who has decided to primary transplant and is willing to participate in the study.
- HSCT candidate undergo mNGS detection before transplantation.
Exclusion Criteria:
- Patients below 14 years ago or above 65 years ago.
- Patients having active infection at the time of letermovir initiation.
- Patient recruited in a clinical study on an anti-CMV trial, or took similar anti-CMV drugs previously.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: mNGS detection before stem cell transplantation
Using letermovir to prevent CMV reactivation for high-risk patients with pre-existing CMV viremia based on the mNGS detection technology before HSCT
|
Letermovir is the world's first and only new drug approved for the prevention of CMV infection.
In 2017, it was approved by the U.S. Food and Drug Administration (FDA) for the prevention of CMV infection and disease in CMV-seropositive adult recipients (R+) of allogeneic hematopoietic stem cell transplantation (allo-HSCT).
It was approved in China on December 31, 2021.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of clinically significant CMV infection with letermovir prevention after HSCT Defined as CMV DNAemia leading to preemptive treatment or presence of CMV disease
Time Frame: Time from registration to event, max 24 weeks
|
The diagnosis of CMV infection is based on CMV-DNA detection of qPCR.
|
Time from registration to event, max 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative incidences of CMV reactivation
Time Frame: Time from registration to event, max 24 weeks
|
The cumulative incidences of CMV reactivation after transplantion.
|
Time from registration to event, max 24 weeks
|
Incidence of Acute and/or chronic graft versus host disease(a/cGVHD)
Time Frame: Time from registration to event, max 24 weeks
|
The diagnosis and grading of aGVHD are based on the modified Glucksberg grading standard.
|
Time from registration to event, max 24 weeks
|
Incidence of transplantation Complications after transplantation
Time Frame: Time from registration to event, max 24 weeks
|
Incidence of transplantation Complications such as mucositis, hepatic veno-occlusive disease(SOS), thrombotic microangiopathy(TMA), interstitial pneumonia, hemorrhagic cystitis, infections etc.
|
Time from registration to event, max 24 weeks
|
Incidence of CMV-related disease mortality
Time Frame: Time from registration to event, max 24 weeks
|
The Incidence of CMV-related disease mortality after transplantation.
|
Time from registration to event, max 24 weeks
|
Incidence of all-cause mortality and non-relapse mortality
Time Frame: Time from registration to event, max 24 weeks
|
The Incidence of all-cause mortality and non-relapse mortality after transplantion.
|
Time from registration to event, max 24 weeks
|
Leukemia-free survival(LFS)
Time Frame: Time from registration to event, max 24 weeks
|
Leukemia-free survival(LFS) is defined as the time from enrollment to relapse of primary disease or death from any cause.
|
Time from registration to event, max 24 weeks
|
Overall survival(OS)
Time Frame: Time from registration to event, max 24 weeks
|
Overall survival(OS) is defined as the time from transplantation to death resulting from any cause.
|
Time from registration to event, max 24 weeks
|
GVHD-free and relapse-free survival(GRFS)
Time Frame: Time from registration to event, max 24 weeks
|
GRFS is defined as the time from graft infusion to the onset of grades 3 to 4 aGVHD, moderate to severe cGVHD, or relapse/disease progression/death.
|
Time from registration to event, max 24 weeks
|
Collaborators and Investigators
Investigators
- Study Chair: Xiaowen Tang, PhD, The First Affiliated Hospital of Soochow University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Disease Attributes
- DNA Virus Infections
- Herpesviridae Infections
- Infections
- Communicable Diseases
- Cytomegalovirus Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Letermovir
Other Study ID Numbers
- mNGS+LMV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic Stem Cell Transplantation
-
Washington University School of MedicineNational Marrow Donor Program; Predictive BioDiagnostics, LLCCompletedHematopoietic Stem Cell Transplantation | Stem Cell Transplantation, Hematopoietic | Transplantation, Hematopoietic Stem CellUnited States
-
University Hospital, GenevaRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation | Autologous Hematopoietic Stem Cell TransplantationSwitzerland
-
Universitaire Ziekenhuizen KU LeuvenUnknownHematopoietic Stem Cell Transplantation | Hematopoietic Stem Cell Transplantation, Allogeneic
-
Hongnan MoUnknownHematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell MobilizationChina
-
National Cancer Institute (NCI)RecruitingHematopoietic Stem Cell TransplantationUnited States
-
Seoul National University HospitalNational Institute of Food and Drug Safety Evaluation (Republic of Korea)RecruitingHematopoietic Stem Cell TransplantationKorea, Republic of
-
University of Michigan Rogel Cancer CenterRecruitingHematopoietic Stem Cell TransplantationUnited States
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...CompletedHematopoietic Stem Cell TransplantationBrazil
-
Seoul National University HospitalCompletedHematopoietic Stem Cell TransplantationKorea, Republic of
-
University of OsloRecruitingHematopoietic Stem Cell TransplantationNorway
Clinical Trials on Letermovir Pill
-
University Medical Centre LjubljanaRecruiting
-
Memorial Sloan Kettering Cancer CenterMerck Sharp & Dohme LLCRecruitingCMV | CMV Infection | Hematopoietic Cell TransplantUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus (CMV) InfectionUnited States, Australia, Colombia, France, Germany, Israel, Japan, Mexico, Poland, Spain, Turkey
-
National Institute of Allergy and Infectious Diseases...Merck Sharp & Dohme LLCCompletedHIV Infections | Cytomegalovirus | CMVUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus Infection | Cytomegalovirus DiseaseJapan
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingCytomegalovirus InfectionFrance
-
Maimónides Biomedical Research Institute of CórdobaMERCK SHARP & DOHME DE ESPAÑA S.A.Not yet recruitingInfections, CytomegalovirusSpain
-
University of PennsylvaniaMerck Sharp & Dohme LLCRecruitingCytomegalovirus Infections | Transplant-Related DisorderUnited States
-
Virginia Commonwealth UniversityMerck Sharp & Dohme LLCRecruitingCMV | Kidney Transplant; ComplicationsUnited States
-
Hospital do Rim e HipertensãoNot yet recruiting